MXPA03005954A - Metodo para tratar enfermedades fibroticas u otras indicaciones iiic. - Google Patents
Metodo para tratar enfermedades fibroticas u otras indicaciones iiic.Info
- Publication number
- MXPA03005954A MXPA03005954A MXPA03005954A MXPA03005954A MXPA03005954A MX PA03005954 A MXPA03005954 A MX PA03005954A MX PA03005954 A MXPA03005954 A MX PA03005954A MX PA03005954 A MXPA03005954 A MX PA03005954A MX PA03005954 A MXPA03005954 A MX PA03005954A
- Authority
- MX
- Mexico
- Prior art keywords
- ylalkyl
- alkyl
- group
- hydrogen
- nitrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Abstract
Se proporciona un metodo para tratar o mejorar ciertas enfermedades fibroticas u otras indicaciones en un animal, incluyendo un humano, que comprende administrar una cantidad eficaz de un compuesto de la farmulg I: Y-Ar+ .X en donde: a) Ar es una cadena de heteroarilo de cinco o seis miembros que tiene un primer nitrogeno en cadena y opcionalmente nitrogenos en cadena, segunda o tercero, con los atomos en cadena restantes siendo carbono, oxigeno o azufre, siempre que el primer nitrogeno de Ar sea un nitrogeno cuaternario y Ar no sea tiazolio, oxazolio imidazolio; b) Y se substituye en el primer nitrogeno en cadena, con la condicion de que si Ar es pirazola, indazola, (1,2,3)-triazola, benzotriazola, o (1,2,4)-triazola, el segundo nitrogeno en cadena se substituye, c) Y es un grupo de la formula -CH(R5)-R6 (como se prefiere en una modalidad), (a) en donde R5 es hidrogeno, alquil-, cicloalquil-, alquenil-, alquinil-, aminoalquil-, hidroxi [C1 a C6] alquilo, dialquilaminoalquil-, (N-[C6 o C10] aril)(N-alquil)aminoalquil-, piperidiri-1- ilalquil-, pirrolidin-1-ilalquilo, azetidinilalquilo, 4-alquilipiperazin-1-ilalquilo, 4-alquilpiperidin-1-ilalquilo, 4-[C6 o C10]arilpiperazin-1-ilalquilo, 4-[C6 o C10]arilpiperidin-1-ilalquilo, azetidin-1-ilalquilo, morfolin-4-ilalquilo, tiomorfolin-4-ilalquilo, piperazin-1-ilalquilo, piperidin-1-ilalquilo, [C6 o C10]arilo o independientemente el mismo que R6; (b) en donde R6 es (1) hidrogeno, alquilo (que puede substituirse por alcoxicarbonil)-, alquenilo, alquinilo, ciano-, cianoalquil-, o Rs, en donde Rs es un [C6 o C10]arilo o un heterociclo que contiene 4-10 atomos en cadena de las cuales 1-3 son heteroatomos seleccionados del grupo que consiste de un oxigeno, nitrogeno y azufre; o (2) un grupo de la formula -W-R7 (como se prefiere en una modalidad), en donde R7 es alquilo, alcoxi, hidroxi, o Rs (como se prefiere en una modalidad), en donde W es -C(=O)- o -S(O)2-; (3) un grupo de la formula -W-OR8 en donde R8 es hidrogeno o alquilo, (4) un grupo de la formula -CH(OH)R5; o (5) un grupo de la formula -W-N(R9)R10, en donde (a) R9 es hidrogeno y R10 es un alquilo o cicloalquilo, opcionalmente substituido; o (b) R9 es hidrogeno o alquilo y R10 es Ar*; o (c) R9 es hidrogeno a alquilo, R10 es un heterociclo que contiene 4-10 atomos en cadena de los cuales 1-3 son heteroatomos seleccionados del grupo que consista de oxigeno, nitrogeno y azufre; o (d) R9 y R10 son ambos grupas alquilo; o (e) R9y R10 junto con N forman un heterociclo que contiene 4-10 atomos en cadena que pueden incorporarse hasta un heteroatomo adicional seleccionado del grupo de N, O o S en la cadena, en donde el heterociclo se substituye opcionalmente; o (f) R9 y R10 son ambos hidrogeno 2 -NH2, y d) X es un anion farmaceuticamente aceptable que puede estar ausente si el compuesto proporciona una sal neutralizante, o una sal farmaceuticamente aceptable del compuesto.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25929400P | 2000-12-29 | 2000-12-29 | |
US25923801P | 2001-01-02 | 2001-01-02 | |
US29624601P | 2001-06-06 | 2001-06-06 | |
PCT/US2001/049833 WO2002067851A2 (en) | 2000-12-29 | 2001-12-28 | Method for treating fibrotic diseases or other indications iiic |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03005954A true MXPA03005954A (es) | 2004-05-24 |
Family
ID=27401209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03005954A MXPA03005954A (es) | 2000-12-29 | 2001-12-28 | Metodo para tratar enfermedades fibroticas u otras indicaciones iiic. |
Country Status (6)
Country | Link |
---|---|
US (2) | US20020183365A1 (es) |
EP (1) | EP1355645A4 (es) |
JP (1) | JP2004525904A (es) |
CA (1) | CA2433425A1 (es) |
MX (1) | MXPA03005954A (es) |
WO (1) | WO2002067851A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276050B2 (en) * | 2004-03-02 | 2007-10-02 | Alan Franklin | Trans-scleral drug delivery method and apparatus |
DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
RS54261B1 (en) * | 2010-05-26 | 2016-02-29 | Adverio Pharma Gmbh | USE OF SGC STIMULATORS, SGC ACTIVATORS, INDIVIDUALLY AND IN COMBINATION WITH PDE5 INHIBITORS FOR SYSTEMIC SCLEROSIS TREATMENT (SSC) |
WO2015011086A1 (en) | 2013-07-25 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH335521A (de) * | 1955-06-02 | 1959-01-15 | Cilag Ag | Verfahren zur Herstellung neuer quaternärer Salze |
GB859452A (en) * | 1958-05-14 | 1961-01-25 | Ilford Ltd | Dicarbocyanines |
JPS55138742A (en) * | 1979-04-17 | 1980-10-29 | Fuji Photo Film Co Ltd | Silver halide emulsion developing method |
NO315930B1 (no) * | 1995-01-18 | 2003-11-17 | Picower Inst For Medical Res T | Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser |
DE69629176T2 (de) * | 1995-01-18 | 2004-06-03 | Alteon Inc. | Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung |
US5656261A (en) * | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
CA2285556A1 (en) * | 1997-04-04 | 1998-10-15 | Smithkline Beecham Corporation | Calcilytic compounds |
US6121300A (en) * | 1998-11-10 | 2000-09-19 | Wagle; Dilip R. | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
HUP0301687A2 (hu) * | 1999-10-06 | 2003-08-28 | Torrent Pharmaceuticals Ltd. | Cukorbetegséggel és öregedéssel kapcsolatos érrendszeri szövődmények kezelésére szolgáló piridinium-vegyületek és eljárás az előállításukra |
AU769940B2 (en) * | 1999-10-06 | 2004-02-12 | Torrent Pharmaceuticals Ltd | Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
HUP0400823A3 (en) * | 2001-04-05 | 2010-06-28 | Torrent Pharmaceuticals Ltd | Heterocyclic compounds for treating aging-related and diabetic vascular complications, their preparation and pharmaceutical compositions containing them |
US20030008817A1 (en) * | 2001-07-03 | 2003-01-09 | Tom Sander | Cross-link reversing agent |
-
2001
- 2001-12-28 WO PCT/US2001/049833 patent/WO2002067851A2/en not_active Application Discontinuation
- 2001-12-28 CA CA002433425A patent/CA2433425A1/en not_active Abandoned
- 2001-12-28 MX MXPA03005954A patent/MXPA03005954A/es unknown
- 2001-12-28 JP JP2002567223A patent/JP2004525904A/ja active Pending
- 2001-12-28 EP EP01273859A patent/EP1355645A4/en not_active Withdrawn
- 2001-12-31 US US10/036,857 patent/US20020183365A1/en not_active Abandoned
-
2003
- 2003-10-23 US US10/691,839 patent/US20040097495A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002067851A3 (en) | 2003-02-06 |
CA2433425A1 (en) | 2002-09-06 |
EP1355645A2 (en) | 2003-10-29 |
JP2004525904A (ja) | 2004-08-26 |
WO2002067851A2 (en) | 2002-09-06 |
US20020183365A1 (en) | 2002-12-05 |
US20040097495A1 (en) | 2004-05-20 |
EP1355645A4 (en) | 2005-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25679A1 (es) | Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer | |
TW430660B (en) | Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them | |
MY116917A (en) | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | |
BG106020A (en) | Inhibitors of impdh enzyme | |
HUP0105113A2 (hu) | Benzoheterociklusos vegyületek és MEK inhibitorokként történő alkalmazásuk és a vegyületeket tartalmazó gyógyászati készítmények | |
CA2409741A1 (en) | Tnf-.alpha. production inhibitors | |
CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
WO2001012169A3 (en) | Method of cancer treatment | |
YU36403A (sh) | Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi | |
TW200727893A (en) | Methods for treating sexual dysfunction | |
MXPA03005954A (es) | Metodo para tratar enfermedades fibroticas u otras indicaciones iiic. | |
TW200735864A (en) | Immediate release pharmaceutical formulation | |
HUT70531A (en) | Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them | |
IL115617A0 (en) | Pharmaceutical composition for prophylaxis and treatment of type i allergic diseases | |
MXPA06000416A (es) | Amidas azaheterociclicas novedosas utiles para tratar el dolor. | |
NZ517315A (en) | New derivatives of A-500359 | |
DE69315836D1 (de) | Pyrazolpyridine für die behandlung der anämie | |
NZ505458A (en) | Succinamide based hydroxamic acid or carboxylic acid thioamides and pharmaceuticals thereof, useful as matrix metalloproteinase inhibitors | |
RS20050954A (en) | Use of bycyclo/2.2.1/heptane derivatives for the preparation of neuroprotective pharmaceutical compositions | |
AU2002253633B2 (en) | 20-hydroxyeicosatetraenoic acid production inhibitors | |
HUP0202340A2 (hu) | Hatóanyagként kondenzált heterociklusos vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NO973963L (no) | Fremgangsmåte for å hemme ovariecancer | |
MXPA06000651A (es) | Uso de derivados de indazol para el tratamiento de dolor neuropatico. | |
AU2001296240A1 (en) | Method for inhibiting cataracts |